Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MYL
CUSIP62853010
Phone44-0-17-0785-3000
Debt
Debt-to-Equity Ratio1.06%
Current Ratio1.13%
Quick Ratio0.73%
Price-To-Earnings
Trailing P/E Ratio8.94
Forward P/E Ratio7.61
P/E Growth1.32
Sales & Book Value
Annual Sales$11.91 billion
Price / Sales1.76
Cash Flow$7.9339 per share
Price / Cash5.14
Book Value$24.81 per share
Price / Book1.64
Profitability
EPS (Most Recent Fiscal Year)$4.56
Net Income$696 million
Net Margins5.84%
Return on Equity19.14%
Return on Assets6.92%
Miscellaneous
Employees35,000
Outstanding Shares514,780,000
Mylan (NASDAQ:MYL) Frequently Asked Questions
What is Mylan's stock symbol?
Mylan trades on the NASDAQ under the ticker symbol "MYL."
How were Mylan's earnings last quarter?
Mylan (NASDAQ:MYL) issued its earnings results on Wednesday, February, 28th. The company reported $1.43 EPS for the quarter, topping the consensus estimate of $1.41 by $0.02. The business earned $3.24 billion during the quarter, compared to the consensus estimate of $3.29 billion. Mylan had a return on equity of 19.14% and a net margin of 5.84%. The firm's revenue was down .9% compared to the same quarter last year. During the same quarter last year, the company earned $1.57 EPS. View Mylan's Earnings History.
When is Mylan's next earnings date?
What guidance has Mylan issued on next quarter's earnings?
Mylan issued an update on its FY18 earnings guidance on Wednesday, April, 11th. The company provided EPS guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus estimate of $5.38. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.
What price target have analysts set for MYL?
19 Wall Street analysts have issued 12 month price targets for Mylan's shares. Their forecasts range from $29.39 to $59.00. On average, they expect Mylan's share price to reach $47.2311 in the next year. View Analyst Ratings for Mylan.
What are Wall Street analysts saying about Mylan stock?
Here are some recent quotes from research analysts about Mylan stock:
- 1. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) The North America segment was down 8%, excluding Epipen, which declined $131.9MM in 4Q17, and $655.4MM in 2017. EU grew 16% in the quarter, and Rest of World grew 12%. 2) Generic drug pricing continued to be a headwind in the U.S. during the quarter. However, favorable pricing on existing products in Europe was a tailwind in 4Q17. 3) The Restasis target action date is in July 2018. The Biosimilar pegfilgrastim target action date is in early June. 4) MYL repurchased 12.4MM shares during 2017, and an additional 9.8MM shares in January 2018. 4) MYL expects to launch generic Adavir and Neulasta in 2018, and has risk-weighted these launches in its 2018 guidance." (3/1/2018)
- 2. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
- 3. Argus analysts commented, "junior version" (8/22/2017)
Are investors shorting Mylan?
Mylan saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 17,578,475 shares, a drop of 14.1% from the March 15th total of 20,463,110 shares. Based on an average daily volume of 4,309,865 shares, the short-interest ratio is presently 4.1 days. Currently, 3.6% of the shares of the stock are sold short.
Who are some of Mylan's key competitors?
Some companies that are related to Mylan include Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN) and Grifols (GRFS).
Has Mylan been receiving favorable news coverage?
Media coverage about MYL stock has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mylan earned a coverage optimism score of 0.08 on Accern's scale. They also assigned media headlines about the company an impact score of 46.25 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Mylan?
Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mylan's stock price today?
One share of MYL stock can currently be purchased for approximately $40.78.
How big of a company is Mylan?
Mylan has a market capitalization of $20.96 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.
How can I contact Mylan?
Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]
MarketBeat Community Rating for Mylan (MYL)
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mylan (NASDAQ:MYL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for Mylan in the last 12 months. Their average twelve-month price target is $47.2311, suggesting that the stock has a possible upside of 15.82%. The high price target for MYL is $59.00 and the low price target for MYL is $29.39. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.74 | 2.68 | 2.61 | 2.61 |
| Ratings Breakdown: | 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $47.2311 | $46.81 | $44.2439 | $40.9619 |
| Price Target Upside: | 15.82% upside | 11.40% upside | 5.56% downside | 5.25% upside |
Mylan (NASDAQ:MYL) Consensus Price Target History
Mylan (NASDAQ:MYL) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Mylan (NASDAQ:MYL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 84.34%
Mylan (NASDAQ MYL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | Paul Campbell | Insider | Sell | 7,030 | $44.01 | $309,390.30 | 17,054 |  |
| 3/6/2018 | Robert J. Coury | Director | Sell | 50,000 | $43.41 | $2,170,500.00 | | |
| 3/2/2018 | Anthony Mauro | Insider | Sell | 12,257 | $40.35 | $494,569.95 | 147,435 | |
| 3/2/2018 | Rajiv Malik | President | Sell | 50,000 | $40.91 | $2,045,500.00 | 503,751 | |
| 3/2/2018 | Robert J. Coury | Director | Sell | 150,000 | $40.10 | $6,015,000.00 | | |
| 1/9/2018 | Heather M. Bresch | CEO | Sell | 75,000 | $45.00 | $3,375,000.00 | | |
| 6/9/2017 | Anthony Mauro | Insider | Sell | 10,000 | $40.00 | $400,000.00 | 140,653 | |
| 6/9/2017 | Rajiv Malik | President | Sell | 25,000 | $40.00 | $1,000,000.00 | 799,855 | |
| 3/23/2017 | Laboratories Abbott | Major Shareholder | Sell | 44,000,000 | $41.60 | $1,830,400,000.00 | | |
| 8/9/2016 | Heather M Bresch | CEO | Sell | 100,200 | $50.00 | $5,010,000.00 | 828,318 | |
| 6/3/2016 | Joseph C Md Maroon | Director | Buy | 1,670 | $44.95 | $75,066.50 | 22,036 | |
| 5/25/2016 | Robert J Cindrich | Director | Buy | 1,190 | $42.47 | $50,539.30 | 13,384 | |
| 5/12/2016 | Melina E Higgins | Director | Buy | 19,900 | $38.68 | $769,732.00 | 1,872 | |
| 5/6/2016 | Melina E Higgins | Director | Buy | 100 | $38.69 | $3,869.00 | 1,872 | |
| 4/28/2016 | Melina E Higgins | Director | Buy | 35,000 | $42.92 | $1,502,200.00 | | |
| 4/5/2016 | Robert J Coury | Chairman | Sell | 217,755 | $45.96 | $10,008,019.80 | 1,334,306 | |
| 3/31/2016 | Joseph C Md Maroon | Director | Buy | 4,337 | $46.36 | $201,063.32 | 16,124 | |
| 3/17/2016 | Mark W Parrish | Director | Buy | 1,705 | $44.00 | $75,020.00 | 31,365 | |
| 3/8/2016 | Wendy Cameron | Director | Buy | 2,190 | $45.69 | $100,061.10 | 66,677 | |
| 3/3/2016 | Robert J Cindrich | Director | Buy | 2,187 | $45.83 | $100,230.21 | 10,322 | |
| 12/17/2015 | John D. Sheehan | CFO | Sell | 34,579 | $55.03 | $1,902,882.37 | 171,251 | |
| 6/15/2015 | Melina E Higgins | Director | Sell | 8,351 | $73.08 | $610,291.08 | | |
| 2/3/2015 | Anthony Mauro | Insider | Sell | 13,255 | $53.15 | $704,503.25 | | |
| 2/3/2015 | Heather M Bresch | CEO | Sell | 411,996 | $53.15 | $21,897,587.40 | | |
| 2/3/2015 | Rajiv Malik | President | Sell | 285,394 | $53.15 | $15,168,691.10 | | |
| 2/3/2015 | Robert J Coury | Chairman | Sell | 947,119 | $52.55 | $49,771,103.45 | | |
| 2/3/2015 | Rodney L Piatt | Director | Sell | 46,000 | $53.15 | $2,444,900.00 | | |
| 11/26/2014 | John D Sheehan | CFO | Sell | 19,475 | $57.50 | $1,119,812.50 | | |
| 11/25/2014 | Heather M Bresch | CEO | Sell | 100,000 | $55.80 | $5,580,000.00 | | |
| 11/25/2014 | Rajiv Malik | President | Sell | 120,000 | $55.78 | $6,693,600.00 | | |
| 11/25/2014 | Robert J Coury | Chairman | Sell | 165,700 | $55.78 | $9,242,746.00 | | |
| 11/24/2014 | Heather M Bresch | CEO | Sell | 80,222 | $55.86 | $4,481,200.92 | | |
| 11/24/2014 | Rajiv Malik | President | Sell | 84,300 | $55.86 | $4,708,998.00 | | |
| 11/24/2014 | Robert J Coury | Chairman | Sell | 105,800 | $55.88 | $5,912,104.00 | | |
| 11/7/2014 | Melina E Higgins | Director | Buy | 14,000 | $52.45 | $734,300.00 | | |
| 9/18/2014 | Neil F Dimick | Director | Sell | 5,432 | $48.26 | $262,148.32 | | |
| 6/19/2014 | Neil F Dimick | Director | Sell | 5,432 | $50.81 | $275,999.92 | | |
| 4/22/2014 | Rajiv Malik | President | Sell | 80,000 | $50.00 | $4,000,000.00 | 289,117 | |
| 4/14/2014 | Heather Bresch | CEO | Sell | 75,000 | $46.07 | $3,455,250.00 | 293,418 | |
| 3/20/2014 | Neil Dimick | Director | Sell | 5,813 | $53.08 | $308,554.04 | 32,136 | |
| 3/14/2014 | C Todd | Director | Sell | 10,000 | $53.00 | $530,000.00 | 23,389 | |
| 3/6/2014 | Harry Korman | COO | Sell | 31,970 | $54.54 | $1,743,643.80 | 133,373 | |
| 3/3/2014 | Anthony Mauro | Insider | Sell | 20,000 | $54.81 | $1,096,200.00 | 25,473 | |
| 3/3/2014 | Daniel Rizzo, Jr. | CAO | Sell | 8,003 | $55.50 | $444,166.50 | 82,296 | |
| 3/3/2014 | Douglas Leech | Director | Sell | 10,000 | $55.40 | $554,000.00 | 36,271 | |
| 1/2/2014 | Neil Dimick | Director | Sell | 5,813 | $43.15 | $250,830.95 | 32,136 | |
| 12/19/2013 | Rodney Piatt | Director | Sell | 10,000 | $41.84 | $418,400.00 | 62,436 | |
| 12/12/2013 | Daniel Rizzo, Jr. | CAO | Sell | 70,683 | $42.04 | $2,971,513.32 | 68,971 | |
| 12/12/2013 | Melina Higgins | Director | Buy | 5,000 | $42.03 | $210,150.00 | | |
| 9/6/2013 | Heather M Bresch | CEO | Sell | 160,000 | $35.35 | $5,656,000.00 | | |
| 6/3/2013 | Neil F Dimick | Director | Sell | 19,994 | $30.51 | $610,016.94 | | |
| 11/27/2012 | Daniel C Rizzo Jr | CAO | Sell | 161,124 | $27.28 | $4,395,462.72 | | |
| 11/2/2012 | Douglas J Leech | Director | Sell | 44,280 | $25.94 | $1,148,623.20 | | |
| 11/1/2012 | Anthony Mauro | Insider | Sell | 12,301 | $25.79 | $317,242.79 | | |
| 10/5/2012 | Anthony Mauro | Insider | Sell | 12,296 | $24.84 | $305,432.64 | | |
(Data available from 1/1/2013 forward)
Mylan (NASDAQ MYL) News Headlines
| Source: |
|
Mylan (NASDAQ:MYL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Mylan (NASDAQ:MYL) Income Statement, Balance Sheet and Cash Flow Statement
Mylan (NASDAQ MYL) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
